Proprotein Convertase Substilisin/Kexin Type 9 Antagonism Reduces Low-Density Lipoprotein Cholesterol in Statin-Treated Hypercholesterolemic Nonhuman Primates-Reference-Cited by-同舟云学术

Proprotein Convertase Substilisin/Kexin Type 9 Antagonism Reduces Low-Density Lipoprotein Cholesterol in Statin-Treated Hypercholesterolemic Nonhuman Primates

Published:2011-10-21 Issue:2 Volume:340 Page:228-236
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Liang Hong,Chaparro-Riggers Javier,Strop Pavel,Geng Tao,Sutton Janette E.,Tsai Daniel,Bai Lanfang,Abdiche Yasmina,Dilley Jeanette,Yu Jessica,Wu Si,Chin S. Michael,Lee Nicole A.,Rossi Andrea,Lin John C.,Rajpal Arvind,Pons Jaume,Shelton David L.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference47 articles.

1. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease

2. The contrasting IgG-binding interactions of human and herpes simplex virus Fc receptors

3. Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9

4. The Proprotein Convertase (PC) PCSK9 Is Inactivated by Furin and/or PC5/6A

5. Missense Mutations in the PCSK9 Gene Are Associated With Hypocholesterolemia and Possibly Increased Response to Statin Therapy

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cholesterol reduction by immunization with a PCSK9 mimic;Cell Reports;2024-06

2. PCSK9 stimulates Syk, PKCδ, and NF-κB, leading to atherosclerosis progression independently of LDL receptor;Nature Communications;2024-03-30

3. PCSK9 Biomarker and Key Modulator for Cardiovascular Disorders: Heralding a New Therapeutic Era and Their Future Perspectives;Current Molecular Pharmacology;2023-12

4. Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody;CPT: Pharmacometrics & Systems Pharmacology;2023-11-22

5. The Link between miRNAs and PCKS9 in Atherosclerosis;Current Medicinal Chemistry;2023-11-16